Human Genome Sciences, a biopharmaceutical issue, has developed a drug called Benlysta as a treatment for the chronic and dangerous illness of Lupus. Medication trials by the FDA have been seeking to answer questions regarding the efficacy and safety of Benlysta for the treatment of Lupus. Benlysta is good news for individuals with Lupus, however Wall Street reduced stock in Human Genome Sciences when reports came out showing that Benlysta treatments might not be as expensive for patients as investors hoped to bank on. Article resource – Human Genome Sciences dissed – Lupus drug disappoints Wall Street by Personal Money Store.
Human Genome Sciences that Benlysta works together with
Wednesday, Human Genome Sciences stock was down a bit. Sales revenue for Benlysta getting not that great is what caused this. Human Genome Sciences had stock-price targets cut by Citigroup and Financial institution of America, reports MarketWatch. This took place before trading perhaps even started. It seems that fearful investors are more worried regarding generating money than they are regarding helping those with Lupus. MarketWatch was able to talk to Financial institution of The United States Analyst Rachel McMinn. She said the Tuesday info from the Food and Drug Administration panel "underscored concerns that Benlysta may have a smaller than anticipated role in lupus treatment."
Great news for Lady Gaga
The first brand new treatment in 50 years for lupus will come from the Human Genome Sciences' Benlysta. About 1.5 million Americans have Lupus. Lady Gaga might be probably the most prominent of them. The body attacks itself when it has Lupus. There are a few common symptoms with it. These contain inflammation of vital organs, aching joints and skin rashes. You will find serious side effects on all lupus treatments at present. Either the remedy side effects or the Lupus symptoms are just what patient has to determine which to live with. There is no remedy.
Not so good news for Wall Street
Those with standard treatment didn't improve almost as much as those given Benlysta in a one-year FDA research that was done for all those with Lupus. However, the drug loses some of its effectiveness after the first year. From $40,000 a patient to $35,000 a patient is how the estimate of Benlysta treatment has actually been changed by McMinn because of this. She reduced Human Genome Sciences to "underperform" from "buy" and cut the price target from $33 a share to $24. A Citigroup analyst told MarketWatch that global sales for Benlysta, which investors had hoped would reach $2.6 billion by 2015, are now merely expected to reach $1.6 billion.
Articles cited
MarketWatch
marketwatch.com/story/human-genome-downgraded-over-lupus-drug-potential-2010-11-17
WebMD
lupus.webmd.com/news/20101114/benlysta-shows-promise-for-lupus
CBS News
cbsnews.com/8301-504763_162-20023092-10391704.html
No comments:
Post a Comment